Plain English Summary
Retatrutide is a triple hormone receptor agonist (GLP-1, GIP, and glucagon) in late-stage clinical trials showing the strongest weight loss results of any obesity drug to date—up to 24% body weight reduction in trials.
What People Use It For
Realistic Expectations
Best Case
Up to 24% body weight loss shown in trials (48 weeks, highest dose)
Common Outcome
Trial data shows 15-20% weight loss at moderate doses
Low / No Response
Unknown until more real-world data available
Side Effects & Risks
Common Side Effects
Warnings
- Not yet FDA approved
- Long-term safety unknown
- Phase 3 trials ongoing
- Not available outside clinical trials
Who This Is Not For
Anyone looking for approved treatments. Only available in clinical trials.
Commonly Confused With
Timeline of Expected Changes
Trial data shows progressive weight loss over 48 weeks
Researchers also explore
Semaglutide
Semaglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes that has become one of the most effective weight loss medications available. It works by mimicking a natural hormone that regulates appetite and blood sugar, helping people feel full faster and longer.
Tirzepatide
Tirzepatide is a dual GIP/GLP-1 receptor agonist that has shown even stronger weight loss results than semaglutide in clinical trials. It targets two hormone pathways instead of one, making it potentially more effective for both weight loss and blood sugar control.
Liraglutide
An FDA-approved GLP-1 receptor agonist used for both type 2 diabetes (Victoza) and weight loss (Saxenda). An earlier-generation option in the GLP-1 family, requiring daily injections versus weekly dosing of newer agents.
GIP (Glucose-dependent Insulinotropic Polypeptide)
GIP is an incretin hormone naturally secreted by the intestine in response to nutrient intake. It plays a critical role in regulating insulin secretion, fat metabolism, and systemic energy balance. While historically viewed primarily as an insulin-stimulating hormone, recent research—particularly involving dual GIP/GLP-1 receptor co-agonists like tirzepatide—highlights its significant role in weight management and metabolic health.
Researcher Sentiment
No votes yet — be the first
Educational Content Only
This is not medical advice. Always consult a licensed healthcare provider before using any compound. No dosing or sourcing guidance is provided.